We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.97%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$752M
AUM Growth
+$105M
Cap. Flow
-$17.7M
Cap. Flow %
-2.36%
Top 10 Hldgs %
46.3%
Holding
87
New
16
Increased
20
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$16.7M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$16M
3
DVAX
Dynavax Technologies
DVAX
+$10.9M
4
NVRO
NEVRO CORP.
NVRO
+$10.2M
5
CHRS icon
Coherus Oncology
CHRS
+$8.85M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$39.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.6M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$28.1M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$27.1M
5
CMRX
Chimerix, Inc.
CMRX
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 88.18%
2 Miscellaneous 11.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
51
DELISTED
Dermira, Inc.
DERM
$2.98M 0.4%
170,000
– –
FOLD
52
DELISTED
Amicus Therapeutics
FOLD
$2.83M 0.38%
+200,000
New +$2.4M
AVEO
53
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.76M 0.37%
+158,772
New +$2.86M
BPMC
54
DELISTED
Blueprint Medicines
BPMC
$2.65M 0.35%
+100,000
New +$2.86M
ATRA icon
55
Atara Biotherapeutics
ATRA
$99.1M
$2.64M 0.35%
+2,000
New +$2.29M
ARAV
56
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.59M 0.34%
28,333
– –
DARE icon
57
Dare Bioscience
DARE
$14.6M
$2.54M 0.34%
4,595
+1,250
+37% +$858K
GNVC
58
DELISTED
GenVec, Inc.
GNVC
$2.4M 0.32%
117,624
-8,660
-7% -$211K
HTGM
59
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$2.24M 0.3%
+1,117
New +$2.85M
KIN
60
DELISTED
Kindred Biosciences, Inc.
KIN
$2.24M 0.3%
328,497
– –
MCRB icon
61
Seres Therapeutics
MCRB
$44.2M
$2.08M 0.28%
+2,500
New +$2.18M
NGNE icon
62
Neurogene
NGNE
$677M
$1.94M 0.26%
13,995
– –
AGRX
63
DELISTED
Agile Therapeutics
AGRX
$1.56M 0.21%
91
– –
VCYT icon
64
Veracyte
VCYT
$3.2B
$1.54M 0.2%
137,990
+2,800
+2% +$27.6K
CLRB icon
65
Cellectar Biosciences
CLRB
$22.3M
$1.53M 0.2%
18
– –
NSTG
66
DELISTED
NanoString Technologies, Inc.
NSTG
$1.23M 0.16%
80,000
-195,000
-71% -$2.61M
CFRX
67
DELISTED
ContraFect Corporation
CFRX
$1.23M 0.16%
+293
New +$1.19M
PVCT
68
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$1.19M 0.16%
+2,200,000
New +$1.79M
ASND icon
69
Ascendis Pharma A/S
ASND
$16.3B
$1.09M 0.14%
61,500
– –
AKBA icon
70
Akebia Therapeutics
AKBA
$259M
$1.03M 0.14%
100,300
– –
BITI
71
DELISTED
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
$999K 0.13%
+50,000
New +$1.04M
SCYX icon
72
SCYNEXIS
SCYX
$41.6M
$873K 0.12%
1,242
– –
GALT icon
73
Galectin Therapeutics
GALT
$374M
$781K 0.1%
286,200
– –
PVCT.WS
74
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
$480K 0.06%
+2,200,000
New +$457K
ADAP
75
DELISTED
Adaptimmune Therapeutics
ADAP
$458K 0.06%
+25,000
New +$429K
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Cormorant Asset Management held 87 positions worth $752M, up 16% from $647M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management's Q2 2015 filing shows 16 new, 20 increased, 11 reduced and 7 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M. The largest sale was Puma Biotechnology, an estimated $39.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q2 2015 buy was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M.
  • Cormorant Asset Management added most to Alder Biopharmaceuticals in Q2 2015, an estimated $16M increase.
  • Cormorant Asset Management's biggest Q2 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $28.1M.
  • Cormorant Asset Management fully exited Puma Biotechnology in Q2 2015, selling an estimated $39.5M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $752M portfolio in Q2 2015.
  • Cormorant Asset Management opened 16 new positions and closed 7 in Q2 2015.
  • Cormorant Asset Management's portfolio value rose 16% quarter-over-quarter to $752M.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.